Hookworm Vaccine Reduces Infection and Combats Anemia in Trial

A new experimental vaccine targeting hookworm infection has shown promising results in early clinical trials, reducing the prevalence of the parasitic disease and offering potential relief for millions affected by anemia, particularly in low-income regions where the parasite is endemic.

The vaccine, developed by researchers at the George Washington University School of Medicine and Health Sciences in collaboration with international partners, demonstrated a significant reduction in hookworm infection rates among participants in a Phase 1 trial conducted in Brazil. According to findings published in the journal Nature Medicine, the vaccine candidate, known as Na-GST-1/Alhydrogel®, induced a strong immune response and lowered parasite burden in vaccinated individuals compared to those receiving a placebo.